Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

Share:

LEAWOOD, Kan., Feb. 12, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ:PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Tuesday, March 12, 2019 at 4:30 p.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2018.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:
1 (866) 364-3820 (U.S.)
1 (855) 669-9657 (Canada)
1 (412) 902-4210 (International)

A replay of the fourth quarter and full year 2018 results teleconference will be available within several hours of the event and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10128673:

1 (877) 344-7529 (U.S.)
1 (855) 669-9658 (Canada)
1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats. As a pioneer in pet therapeutics, Aratana's mission is to deliver safe and effective therapeutics that elevate the standard of care in veterinary medicine. We work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
ir@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
media@aratana.com
(913) 353-1050

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-report-fourth-quarter-and-full-year-2018-financial-results-300794037.html

SOURCE Aratana Therapeutics, Inc.

View Comments and Join the Discussion!